Kymera Therapeutics KYMR
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Kymera Therapeutics (KYMR) Core Market Data and Business Metrics
Latest Closing Price
$26.36Price-Earnings Ratio
-8.85Total Outstanding Shares
64.94 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
500 North Beacon Street, 4th Floor, Watertown, MA, 02472
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 693,823 Shares | 11.3 | 3/14/2025 | 7,842,166 Shares |
| 788,404 Shares | 9.61 | 2/28/2025 | 7,575,085 Shares |
| 464,379 Shares | 15.8 | 2/14/2025 | 7,339,095 Shares |
| 471,507 Shares | 16.31 | 1/31/2025 | 7,690,384 Shares |
| 544,355 Shares | 15.34 | 1/15/2025 | 8,352,487 Shares |
| 500,674 Shares | 17.52 | 12/31/2024 | 8,772,474 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $608.85 Million |
| Net Cash Flow From Operating Activities, Continuing | $-194.50 Million |
| Net Cash Flow | $10.27 Million |
| Net Cash Flow From Investing Activities | $-404.08 Million |
| Net Cash Flow From Investing Activities, Continuing | $-404.08 Million |
| Net Cash Flow From Operating Activities | $-194.50 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Gross Profit | $0 |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Cost Of Revenue | $47.07 Million |
| Diluted Average Shares | $75.04 Million |
| Operating Expenses | $308.71 Million |
| Benefits Costs and Expenses | $270.93 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-224.79 Million |
| Other Comprehensive Income/Loss | $-933,000 |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-224.79 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Noncontrolling Interest | $0 |
| Noncurrent Liabilities | $74.65 Million |
| Current Assets | $510.27 Million |
| Noncurrent Assets | $467.77 Million |
| Liabilities And Equity | $978.03 Million |
| Other Current Liabilities | $61.78 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||